Fecal microbiota in pediatric inflammatory bowel disease and its relation to inflammation

American Journal of Gastroenterology

Volumn 110, Issue 6, 2015, Pages 921-930

  Kolho, Kaija Leena ^a   Korpela, Katri ^a   Jaakkola, Tytti ^a   Pichai, Madharasi V A ^b   Zoetendal, Erwin G ^c   Salonen, Anne ^a   De Vos, Willem M ^a,c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b THE UNIVERSITY OF AUCKLAND   (New Zealand)

^c WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; BIOLOGICAL MARKER; BUTYRIC ACID; CALGRANULIN; GLUCOCORTICOID; INFLIXIMAB; MESALAZINE; METHOTREXATE; PROBIOTIC AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ARTICLE; BACTERIAL STRAIN; BIFIDOBACTERIUM; BLOOD SAMPLING; CHILD; CLOSTRIDIUM; CONTROLLED STUDY; CROHN DISEASE; DIAGNOSTIC TEST ACCURACY STUDY; ENTERITIS; EUBACTERIUM; EUBACTERIUM RECTALE; FECES; FECES MICROFLORA; FEMALE; GRAM POSITIVE BACTERIUM; HUMAN; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MICROBIAL DIVERSITY; PEDIATRICS; PHYLOGENY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; TERTIARY CARE CENTER; TREATMENT DURATION; TREATMENT RESPONSE; ULCERATIVE COLITIS; ANTAGONISTS AND INHIBITORS; BACTEROIDES FRAGILIS; CASE CONTROL STUDY; CHEMISTRY; COLITIS, ULCERATIVE; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGY; MICROFLORA; MOLECULAR TYPING;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; BACTEROIDES FRAGILIS; BIFIDOBACTERIUM; CASE-CONTROL STUDIES; CHILD; CLOSTRIDIUM; COLITIS, ULCERATIVE; CROHN DISEASE; EUBACTERIUM; FECES; FEMALE; HUMANS; INFLAMMATION; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MICROBIOTA; MOLECULAR TYPING; PROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84930760898     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2015.149     Document Type: Article

References (54)

1. Molodecky N, Shian Soon I, Rabi DM et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142: 46-54
2. Benchimol EI, Fortinsky KJ, Gozdyra P et al. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis 2011;17: 423-39.
3. Lehtinen P, Ashorn M, Iltanen S et al. Incidence trends of pediatric inflammatory bowel disease in Finland, 1987-2003, a nationwide study. Inflamm Bowel Dis 2011;17: 1778-83.
4. Kappelman MD, Porter CQ, Galanko JA et al. Utilization of healthcare resources by U.S. children and adults with inflammatory bowel disease. Inflamm Bowel Dis 2011;17: 62-8.
5. Jostins L, Ripke S, Weersma RK et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012;49: 119-24.
6. Gearry RB, Richardson AK, Frampton CM et al. Population-based cases control study of inflammatory bowel disease risk factors. J Gastroenterol Hepatol 2010;25: 325-33.
7. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 2014;146: 1489-99.
8. Cox LM, Yamanishi S, Sohn J et al. Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. Cell 2014;158: 705-21.
9. Hviid A, Svanstr? H, Frisch M. Antibiotic use and inflammatory bowel diseases in childhood. Gut 2011;60: 49-54.
10. Virta L, Auvinen A, Helenius H et al. Association of repeated exposure to antibiotics with the development of pediatric Crohn's disease-a nationwide, register-based Finnish case-control study. Am J Epidemiol 2012;175: 775-84.
11. Ruemmele FM, Veres G, Kolho KL et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis 2014;8: 1179-207.
12. Turner D, Levine A, Escher JC et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr 2012;55: 340-61.
13. Henderson P, Anderson NH, Wilson DC. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2014;109: 637-45.
14. Sipponen T. Diagnostics and prognostics of inflammatory bowel disease with fecal neutrophil-derived biomarkers calprotectin and lactoferrin. Dig Dis 2013;31: 336-44.
15. Mart-de-Carpi J, Pociello N, Varea V. Long-term efficacy of adalimumab in paediatric Crohn's disease patients na?e to other anti-TNF therapies. J Crohns Colitis 2010;4: 594-8.
16. de Bie CI, Escher JC, de Ridder L. Antitumor necrosis factor treatment for pediatric inflammatory bowel disease. Inflamm Bowel Dis 2012;18: 985-1002.
17. de Ridder L, Rings EH, Damen GM et al. Infliximab dependency in pediatric Crohn?s disease: long-term follow-up of an unselected cohort. Inflamm Bowel Dis 2008;14: 353-8.
18. Hyams JS, Lerer T, Griffiths A et al. Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. Inflamm Bowel Dis 2009;15: 816-22.
19. Kolho KL, Sipponen T. The long-term outcome of anti-tumor necrosis factor-therapy related to fecal calprotectin values during induction therapy in pediatric inflammatory bowel disease. Scand J Gastroenterol 2014;49: 434-41.
20. Zoetendal EG, Rajilic-Stojanovic M, de Vos WM. High-throughput diversity and functionality analysis of the gastrointestinal tract microbiota. Gut 2008;57: 1605-15.
21. Willing BP, Dicksved J, Halfvarson J et al. A pyrosequencing study in twins shows that gastrointestinal microbial profi les vary with inflammatory bowel disease phenotypes. Gastroenterology 2010;139: 1844-54.
22. Rajili-Stojanovi M, Shanahan F, Guarner F et al. Phylogenetic analysis of dysbiosis inulcerative colitis during remission. Inflamm Bowel Dis 2013;19: 481-8.
23. Gevers D, Kugathasan S, Denson LA et al. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe 2014;15: 382-92.
24. Sokol H, Pigneur B, Watterlot L et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 2008;105: 16731-6.
25. Joossens M, Huys G, Cnockaert M. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaff ected relatives. Gut 2011;60: 631-7.
26. Png CW, Lind? SK, Gilshenan KS et al. Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am J Gastroenterol 2010;105: 2420-8.
27. Michail S, Durbin M, Turner D et al. Alterations in the gut microbiome of children with severe ulcerative colitis. Inflamm Bowel Dis 2012;18: 1799-808.
28. Levine A, Koletzko S, Turner D et al. ESPGHAN revised Porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr 2014;58: 795-806.
29. Haapami J, Roine RP, Sintonen H et al. Health-related quality of life in paediatric patients with inflammatory bowel disease related to disease activity. J Paediatr Child Health 2011;47: 832-7.
30. M?k?en T, Wikstr? A, Heiskanen K et al. Skin reactions during anti-TNF? therapy for pediatric inflammatory bowel disease: a 2-year prospective study. Inflamm Bowel Dis 2014;20: 1309-15.
31. Sipponen T, Kolho K L. Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease. Scand J Gastroenterol 2015;50: 74-80.
32. Kolho KL, Raivio T, Lindahl H et al. Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease. Scand J Gastroenterol 2006;41: 720-5.
33. Hnen A, Sipponen T, Kolho KL. Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels. World J Gastroenterol 2011;17: 5166-71.
34. Salonen A, Nikkila J, Jalanka-Tuovinen J et al. Comparative analysis of fecal DNA extraction methods with phylogenetic microarray: Effective recovery of bacterial and archaeal DNA using mechanical cell lysis. J Microbiol Methods 2010;81: 127-34.
35. Rajilic-Stojanovic M, Heilig HG, Molenaar D et al. Development and application of the human intestinal tract chip, a phylogenetic microarray: analysis of universally conserved phylotypes in the abundant microbiota of young and elderly adults. Environ Microbiol 2009;11: 1736-51.
36. Lahti L, Torrente A, Elo LL et al. A fully scalable online pre-processing algorithm for short oligonucleotide microarray atlases. Nucleic Acids Res 2013;41: e110.
37. R Development Core Team. R: A Language and Environment for Statistical Computing R Foundation for Statistical Computing: Vienna, Austria, 2011.
38. Oksanen J, Blanchet FG, Kindt R et al. Vegan: Community Ecology Package. R package version 2.0-6 2014.
39. Pebesma EJ. Multivariable geostatistics in S: the gstat package. Comput Geosci 2004;30: 683-91.
40. Pinheiro J, Bates D, DebRoy S et al. nlme: Linear and Nonlinear Mixed Effects Models. R package version 3.1-108 2013.
41. Robin X, Turck N, Hainard A et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011;12: 77.
42. Burnham KP, Anderson DR. Multimodel inference-understanding AIC and BIC in model selection. Sociol Methods Res 2014;33: 261-304.
43. Claesson MJ, O'Sullivan O, Wang Q et al. Comparative analysis of pyrosequencing and a phylogenetic microarray for exploring microbial community structures in the human distal intestine. PLoS One 2009;4: e6669.
44. Huttenhower C, Kostic AD, Xavier RJ. Inflammatory bowel disease as a model for translating the microbiome. Immunity 2014;40: 843-54.
45. Chassaing B, Darfeuille-Michaud A. The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011;140: 1720-8.
46. Machiels K, Joossens M, Sabino J et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defi nes dysbiosis in patients with ulcerative colitis. Gut 2014;63: 1275-83.
47. Sipponen T, Savilahti E, Kkknen P et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis 2008;14: 1392-8.
48. De Vos M, Dewit O, D'Haens G et al. Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF na?e patients with ulcerative colitis. J Crohns Colitis 2012;6: 557-62.
49. Wright EK, Kamm MA, De Cruz P. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease following surgery. Gastroenterology 2015;148: 938-47.
50. Lahti L, Salojarvi J, Salonen A et al. Tipping elements in the human intestinal ecosystem. Nat Comm 2014;5: 4344.
51. Biagi E, Nylund L, Candela M et al. Th rough ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. PLoS One 2010;5: e10667.
52. Korpela K, Flint HJ, Johnstone AM et al. Gut microbiota signatures predict host and microbiota responses to dietary interventions in obese individuals. PLoS One 2014;9: e90702.
53. Nwosu FC, Thorkildsen LT, Avershina E et al. Age-dependent fecal bacterial correlation to inflammatory bowel disease for newly diagnosed untreated children. Gastroenterol Res Pract 2013;2013: 302-398.
54. Molander P, Bjkesten CG, Mustonen H et al. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNF? blocking agents. Inflamm Bowel Dis 2012;18: 2011-7